All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
Powering insights from Cortellis. Link to Cortellis page on Clarivate website.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing the state of COVID-19 testing
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 27, 2021
Home
» Regeneron pauses dosing in phase II trial of garetosmab for fibrodysplasia ossificans progressiva
Regeneron pauses dosing in phase II trial of garetosmab for fibrodysplasia ossificans progressiva
Published at: Nov. 3, 2020
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=174702
BioWorld Science
Related Articles
Patient dosing underway in phase Ib/II study of NP-137 for endometrial or cervix carcinoma
Dosing begins in phase I/II study of TP-0184 as treatment of anemia in patients with MDS